CEL-SCI (CEL-SCI) Short Percentage of Float

View and export this data going back to 1991. Start your Free Trial

What is CEL-SCI Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of CEL-SCI's Short Percentage of Float

For the Biotechnology subindustry, CEL-SCI's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CEL-SCI's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CEL-SCI's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where CEL-SCI's Short Percentage of Float falls into.

CEL-SCI (CEL-SCI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CEL-SCI Corp (AMEX:CVM) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

LSRM:Germany LSRM:Germany

Address

8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182

Website

https://www.cel-sci.com

CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The company is focused on activating the immune system to fight cancer and infectious diseases. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.

Executives

Gail K Naughton	director	C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Peter R Young	director	8229 BOONE BLVD, STE 802, VIENNA VA 22182
John Cipriano	officer: Senior Vice President	8229 BOONE BLVD, SUITE 802, VIENNA VA 22182
Robert Eugene Watson	director	245 N. HIGHLAND AVE NE, SUITE 230-296, ATLANTA GA 30307
Bruno Jean-marie Baillavoine	director	8229 BOONE BLVD., SUITE 802, VIENNA VA 22182
Eyal Talor	officer: Chief Scientific Officer	8229 BOONE BLVD, STE 802, VIENNA VA 22182
Geert R Kersten	director, officer: Chief Executive Officer	8229 BOONE BLVD, STE 802, VIENNA VA 22182
Daniel H Zimmerman	officer: Sr. Vice President, Research	8229 BOONE BLVD, STE 802, VIENNA VA 22182
Patricia B Prichep	officer: Sr. Vice President, Operations	8229 BOONE BLVD., SUITE 802, VIENNA VA 22182
Clara Maximilian De	director, officer: President
C Richard Kinsolving	director	8229 BOONE BLVD, STE 802, VIENNA VA 22182
Alexander G Esterhazy	director	8229 BOONE BLVD, STE 802, VIENNA VA 22182